Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Rezolute Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
RZLT
Nasdaq
2834
https://www.rezolutebio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Rezolute Inc
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
- Apr 23rd, 2024 12:00 pm
Rezolute Reaches US$75m Market Cap Benefiting Insider Stock Buying
- Mar 27th, 2024 11:31 am
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
- Mar 6th, 2024 12:30 pm
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
- Feb 13th, 2024 9:05 pm
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
- Jan 24th, 2024 1:00 pm
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
- Jan 23rd, 2024 1:00 pm
Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism
- Dec 14th, 2023 1:00 pm
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
- Dec 13th, 2023 1:00 pm
Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"
- Nov 24th, 2023 4:14 pm
Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day
- Nov 17th, 2023 1:00 pm
Rezolute Reports First Quarter Fiscal 2024 Results
- Nov 13th, 2023 9:05 pm
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
- Oct 17th, 2023 12:00 pm
Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
- Oct 11th, 2023 12:00 pm
Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 71% Above Its Share Price
- Oct 2nd, 2023 10:12 am
Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
- Sep 14th, 2023 8:05 pm
Rezolute to Participate in Upcoming Investor Conferences in September
- Sep 6th, 2023 11:00 am
Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism
- Jun 27th, 2023 8:05 pm
Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease
- Jun 1st, 2023 4:45 pm
Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress
- May 11th, 2023 8:05 pm
Scroll